Brain Perfusion Imaging Under Acetazolamide Challenge for Detection of Impaired Cerebrovascular Reserve Capacity: Positive Findings with <sup>15</sup>O-Water PET in Patients with Negative <sup>99m</sup>Tc-HMPAO SPECT Findings.
Where this comes from
- Record sourced from PubMed, PMID 28729429.
- Also identified by DOI 10.2967/jnumed.117.195818.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cerebrovascular reserve capacity (CVRC) is an important parameter for treatment decisions in chronic cerebrovascular diseases. It can be assessed by measuring the acetazolamide-induced change in regional cerebral blood flow using SPECT with <sup>99m</sup>Tc-labeled hexamethylpropyleneamine oxime (<sup>99m</sup>Tc-HMPAO) or PET with <sup>15</sup>O-water. <b>Methods:</b> Our database was searched for patients with moyamoya vasculopathy or atherosclerotic cerebrovascular disease who had undergone <sup>15</sup>O-water PET after normal <sup>99m</sup>Tc-HMPAO SPECT results with respect to CVRC. <sup>15</sup>O-water PET was analyzed visually and quantitatively. Quantitative analysis was based on parametric CVRC maps generated by voxelwise image subtraction. <b>Results:</b> The search identified 18 patients (43 ± 15 y, 12 moyamoya vasculopathy). PET revealed impaired CVRC in 8 patients (44%). Quantitative analysis confirmed the positive visual findings in <sup>15</sup>O-water PET and the negative findings in <sup>99m</sup>Tc-HMPAO SPECT. <b>Conclusion:</b><sup>15</sup>O-water PET enables detection of impaired CVRC in a considerable fraction of symptomatic patients with stenoocclusion and negative <sup>99m</sup>Tc-HMPAO SPECT.
Medical subject headings
- Acetazolamide
- Brain
- Cerebrovascular Circulation
- Oxygen Radioisotopes
- Technetium Tc 99m Exametazime
- Tomography, Emission-Computed, Single-Photon
- Water